Royalty Pharma Dirección

Dirección controles de criterios 3/4

Royalty Pharma's El consejero delegado es Pablo Legorreta , nombrado en Jan 1996, tiene un mandato de 28.08 años. posee directamente 0.82% de las acciones de la empresa, con un valor de $139.85M . La antigüedad media del equipo directivo y del consejo de administración es de 2.2 años y 3.7 años, respectivamente.

Información clave

Pablo Legorreta

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	28.3yrs
Participación del CEO	0.8%
Permanencia media de la dirección	2.3yrs
Promedio de permanencia en la Junta Directiva	3.8yrs

Actualizaciones recientes de la dirección

Recent updates

Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

May 12

Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20

Apr 20

Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20

Jan 16

Royalty Pharma to co-fund development of schizophrenia drug with Merck

Oct 12

Royalty Pharma: Strategic Royalty Interest Acquisition To Drive Significant Growth

Aug 18

Royalty Pharma declares $0.19 dividend

Jul 15

Royalty Pharma: Unique Diversification, Bear Market Performer

May 26

The Price Is Right For Royalty Pharma plc (NASDAQ:RPRX)

Apr 25

Royalty Pharma Offers A Unique Long-Term Investment Opportunity

Mar 01

Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To US$0.19

Jan 25

Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At US$0.19

Jan 11

Royalty Pharma: A Pharma-Like Company Without The Same Risks

Dec 27

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Pablo Legorreta en comparación con los beneficios de Royalty Pharma?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	US$1b
Sep 30 2023	n/a	n/a	US$184m
Jun 30 2023	n/a	n/a	US$255m
Mar 31 2023	n/a	n/a	US$332m
Dec 31 2022	n/a	n/a	US$43m
Sep 30 2022	n/a	n/a	US$507m
Jun 30 2022	n/a	n/a	US$466m
Mar 31 2022	n/a	n/a	US$602m
Dec 31 2021	US$50m	US$8m	US$620m
Sep 30 2021	n/a	n/a	US$783m
Jun 30 2021	n/a	n/a	US$972m
Mar 31 2021	n/a	n/a	US$493m
Dec 31 2020	US$56m	n/a	US$495m
Sep 30 2020	n/a	n/a	US$2b
Jun 30 2020	n/a	n/a	US$2b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	US$29m	n/a	US$2b

Compensación vs. Mercado: Datos insuficientes para determinar si la remuneración total de Pablo es razonable en comparación con empresas de tamaño similar en el mercado US.

Compensación vs. Ingresos: Pabloha sido coherente con los resultados de la empresa en el último año.

CEO

Pablo Legorreta (58 yo)

28.3yrs

Permanencia

Mr. Pablo Gerardo Legorreta serves as Chairman of the Board at ProKidney Corp. He serves as the Chief Executive Officer and Co-Founder at RP Management, LLC. He also serves as Chairman of the Board at Roya...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Pablo Legorreta	Founder	28.3yrs	sin datos	0.82% $ 145.8m
Terrance Coyne	Executive VP & CFO	no data	US$4.35m	0.19% $ 33.4m
George Lloyd	Executive VP of Investments & Chief Legal Officer	1.5yrs	US$4.35m	0.24% $ 42.8m
Christopher Hite	Vice Chairman & Executive VP	4yrs	US$4.35m	0.016% $ 2.8m
Marshall Urist	Executive VP and Head of Research & Investments	3.3yrs	US$4.35m	0.015% $ 2.6m
Arthur McGivern	Executive Vice President of Investments & General Counsel	1.5yrs	sin datos	sin datos
Ashwin Pai	Executive Vice President of Investments	less than a year	sin datos	sin datos
Kristin Stafford	Senior VP & Chief Accounting Officer	no data	sin datos	sin datos
Eric Schneider	Senior VP & Chief Technology Officer	less than a year	sin datos	sin datos
James Reddoch	Executive VP of Investments & Chief Scientific Officer	3.3yrs	US$3.40m	0.19% $ 33.6m
George Grofik	Senior VP and Head of Investor Relations & Communications	no data	sin datos	sin datos
Alessandra Sassun	Senior VP & Head of Human Capital	2.3yrs	sin datos	sin datos

2.3yrs

Permanencia media

56yo

Promedio de edad

Equipo directivo experimentado: RPRXEl equipo directivo de la empresa se considera experimentado (2 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Pablo Legorreta	Founder	28.3yrs	sin datos	0.82% $ 145.8m
David Hodgson	Independent Director	1.8yrs	US$452.45k	0.0019% $ 344.5k
Rory Riggs	Director	3.8yrs	sin datos	0.073% $ 13.0m
Ted Love	Independent Director	3.8yrs	US$423.37k	0.0065% $ 1.2m
Errol De Souza	Independent Director	3.8yrs	US$423.37k	0.013% $ 2.3m
Henry Fernandez	Lead Independent Director	3.8yrs	US$423.37k	0.021% $ 3.7m
Gregory Norden	Independent Director	3.8yrs	US$423.37k	0.013% $ 2.3m
Bonnie Bassler	Independent Director	3.8yrs	US$423.37k	0.0090% $ 1.6m
Mario Giuliani	Director	3.8yrs	sin datos	12.08% $ 2.1b
Catherine Engelbert	Independent Director	3.8yrs	US$423.37k	0.0057% $ 1.0m

3.8yrs

Permanencia media

64.5yo

Promedio de edad

Junta con experiencia: La junta directiva de RPRX se considera experimentada (3.5 años de antigüedad promedio).

Royalty Pharma Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Director notifies of intention to sell stock

Director recently sold US$7.1m worth of stock

Director recently sold US$19m worth of stock

Director notifies of intention to sell stock

Royalty Pharma Appoints Eric Schneider as Chief Technology Officer

Executive VP & CFO recently sold US$2.3m worth of stock

Recent updates

Royalty Pharma plc to Report Q1, 2024 Results on May 09, 2024

Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?

Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem

Consensus EPS estimates increase by 79%

Royalty Pharma: Solid Operational Performance

Full year 2023 earnings released: EPS: US$2.54 (vs US$0.098 in FY 2022)

Upcoming dividend of US$0.21 per share at 2.9% yield

Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.21

Royalty Pharma plc to Report Q4, 2023 Results on Feb 15, 2024

Royalty Pharma: One Of The Best Names In Pharmaceuticals

Royalty Pharma plc Declares Dividend for the First Quarter of 2024, Payable on March 15, 2024

Consensus EPS estimates increase by 68%

Director notifies of intention to sell stock

Director recently sold US$7.1m worth of stock

Royalty Pharma plc's (NASDAQ:RPRX) Share Price Matching Investor Opinion

Director recently sold US$19m worth of stock

Director notifies of intention to sell stock

Consensus EPS estimates increase by 94%

Third quarter 2023 earnings released: EPS: US$0.16 (vs US$0.33 in 3Q 2022)

Upcoming dividend of US$0.20 per share at 2.9% yield

Consensus EPS estimates increase by 55%

Consensus EPS estimates increase by 15%

Royalty Pharma Appoints Eric Schneider as Chief Technology Officer

Executive VP & CFO recently sold US$2.3m worth of stock

Executive VP & CFO notifies of intention to sell stock

Upcoming dividend of US$0.20 per share at 2.6% yield

Second quarter 2023 earnings released: EPS: US$0.51 (vs US$0.70 in 2Q 2022)

Insufficient new directors

Royalty Pharma plc Declares Dividend on Class A Ordinary Shares for the Third Quarter of 2023, Payable on September 15, 2023

Executive VP & CFO recently sold US$2.3m worth of stock

Executive VP & CFO notifies of intention to sell stock

Founder recently bought US$3.8m worth of stock

Royalty Pharma plc to Report Q2, 2023 Results on Aug 08, 2023

Insider recently sold US$6.5m worth of stock

Insider notifies of intention to sell stock

Director notifies of intention to sell stock

Founder recently bought US$7.7m worth of stock

Consensus EPS estimates increase by 243%

Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

Upcoming dividend of US$0.20 per share at 2.4% yield

First quarter 2023 earnings released: EPS: US$0.77 (vs US$0.12 in 1Q 2022)

Consensus EPS estimates increase by 46%

Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20

Director recently sold US$5.1m worth of stock

Insider recently sold US$932k worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of US$0.20 per share at 2.1% yield

Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20

Royalty Pharma plc to Report Q4, 2022 Results on Feb 15, 2023

Consensus forecasts updated

Royalty Pharma Declares First Quarter 2023 Dividend, Payable on March 15, 2023

Royalty Pharma Announces Expansion of Senior Leadership Team

Director recently sold US$2.5m worth of stock

Director recently sold US$16m worth of stock

Director notifies of intention to sell stock

Director recently sold US$5.1m worth of stock

Consensus forecasts updated

High number of new and inexperienced directors

Upcoming dividend of US$0.19 per share

Royalty Pharma Declares Fourth Quarter 2022 Dividend, Payable on December 15, 2022

Royalty Pharma plc Announces Executive Changes

Royalty Pharma to co-fund development of schizophrenia drug with Merck

Royalty Pharma plc to Report Q3, 2022 Results on Nov 08, 2022

Director recently sold US$43m worth of stock

Royalty Pharma: Strategic Royalty Interest Acquisition To Drive Significant Growth

Director recently sold US$2.0m worth of stock

Upcoming dividend of US$0.19 per share

Second quarter 2022 earnings: EPS misses analyst expectations

Royalty Pharma plc (NasdaqGS:RPRX) completed the acquisition of 85% stake in Theravance Respiratory Company, LLC.